**Supp Figure 1** **A** Kaplan Meier Curve of relapse free survival in the in-house dataset based on GR gene expression above (high) and below (low) the median split into the St Gallen subgroups (i) Luminal A (N=77), (ii) Luminal B HER2 positive (N=61), (iii) Luminal B HER2 negative (N=30) (iv) HER2 Enriched (N=37).

**B** Kaplan Meier curve of relapse free survival in anthracycline treated TNBC patients in TMA #2 and TMA #4 combined (N=105).

**Supp Table 1** Summary of assigned IHC H-scores in the tumour and stromal compartments in TMAs #1-4.

| TMA #1 (N=57) | Tumour Score | Cases | Stroma Score | Cases |
|---|---|---|---|---|
| | 0 | 14 | 0 | 3 |
| | 1-100 | 32 | 1-100 | 10 |
| | 101-200 | 6 | 101-200 | 21 |
| | 201-300 | 5 | 201-300 | 23 |
| **TMA #2 (N=64)** | **Tumour Score** | **Cases** | **Stroma Score** | **Cases** |
| | 0 | 16 | 0 | 6 |
| | 1-100 | 30 | 1-100 | 10 |
| | 101-200 | 12 | 101-200 | 15 |
| | 201-300 | 6 | 201-300 | 33 |
| **TMA #3 (N=112)** | **Tumour Score** | **Cases** | **Stroma Score** | **Cases** |
| | 0 | 19 | 0 | 3 |
| | 1-100 | 43 | 1-100 | 7 |
| | 101-200 | 35 | 101-200 | 37 |
| | 201-300 | 15 | 201-300 | 65 |
| **TMA #4 (N=62)** | **Tumour Score** | **Cases** | **Stroma Score** | **Cases** |
| | 0 | 26 | 0 | 6 |
| | 1-100 | 13 | 1-100 | 6 |
| | 101-200 | 12 | 101-200 | 19 |
| | 201-300 | 11 | 201-300 | 31 |

**Supp. Table 2** Log rank hazard ratios, 95% confidence intervals and p-values for survival analysis of metastasis/event free survival dichotomised based on below (low) or above (high) median gene expression of GR in the publicly available datasets, GSE58812 and GSE31519, respectively

|  |  | N (n) | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| **Metastasis Free Survival** |  | 107 (31) |  |  |  |
| **GR** | Low | 54 (20) | 1 |  |  |
|  | High | 53 (11) | 0.4843 | 0.2392-0.9805 | 0.0478* |
| **Event Free Survival** |  | 62 (21) |  |  |  |
| **GR** | Low | 31 (14) | 1 |  |  |
|  | High | 31 (7) | 0.4108 | 0.1739-0.9703 | 0.0432* |

**Supp. Table 3** Log rank hazard ratios, 95% confidence intervals and p-values for survival analysis of metastasis/event free survival dichotomised based on below (low) or above (high) median gene expression of GR in the publicly available dataset, GSE7390.

| **GSE 7390** |  | N (n) | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| **Relapse Free Survival** |  | 64 (32) |  |  |  |
| **GR** | Low | 32 (11) | 1 |  |  |
|  | High | 32 (21) | 2.553 | 1.267-5.142 | 0.0087** |
| **Overall Survival** |  | 64 (32) |  |  |  |
| **GR** | Low | 32 (8) | 1 |  |  |
|  | High | 32 (17) | 2.615 | 1.189-5.751 | 0.0196* |

**Supp. Table 4** Log rank hazard ratios, 95% confidence intervals and p-values for survival analysis relapse free/overall survival stratified by high or low GR IHC expression in (A) TMA #1 and (B) TMA #2.

**A**

| TMA #1 | | N (n) | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| **Relapse Free Survival** | | 57 (16) | | | |
| **GR** | Low | 43 (12) | 1 | | |
| | High | 14 (4) | 0.8724 | 0.2917-2.609 | 0.8122 |
| **Overall Survival** | | 57 (12) | | | |
| **GR** | Low | 42 (12) | 1 | | |
| | High | 15 (0) | 0.2296 | 0.06689-0.7882 | 0.0194* |

**B**

| TMA #2 | | N (n) | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| **Relapse Free Survival** | | 64 (26) | | | |
| **GR** | Low | 58 (25) | 1 | | |
| | High | 6 (1) | 0.3189 | 0.09401-1.082 | 0.2365 |
| **Overall Survival** | | 63 (18) | | | |
| **GR** | Low | 57 (18) | 1 | | |
| | High | 6 (0) | 0.3201 | 0.07484-1.370 | 0.1246 |

**Supp. Table 5** Log rank hazard ratios, 95% confidence intervals and p-values for survival analysis relapse free/overall survival stratified by high or low GR IHC expression in (A) CMF treated patients in TMA #3 and (B) Taxane treated patients in TMA #3.

| A TMA #3 CMF | | N (n) | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| **Relapse Free Survival** | | 77 (32) | | | |
| **GR** | Low | 63 (27) | 1 | | |
| | High | 14 (5) | 0.7407 | 0.3115-1.761 | 0.5343 |
| **Overall Survival** | | 77 (28) | | | |
| **GR** | Low | 63 (23) | 1 | | |
| | High | 14 (5) | 0.9010 | 0.3534-2.298 | 0.8324 |

| B TMA #3 Taxane | | N (n) | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| **Relapse Free Survival** | | 18 (5) | | | |
| **GR** | Low | 13 (2) | 1 | | |
| | High | 5 (3) | 4.939 | 0.6210-39.28 | 0.2365 |
| **Overall Survival** | | 18 (3) | | | |
| **GR** | Low | 13 (2) | 1 | | |
| | High | 5 (1) | 1.424 | 0.1079-18.79 | 0.7717 |

**Supp. Table 6** Log rank hazard ratios, 95% confidence intervals and p-values for survival analysis relapse free/overall survival stratified by high or low GR IHC expression in (A) All patients in TMA #4 and (B) Anthracycline treated patients in TMA #4.

**A**

| TMA #4 All | | N (n) | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| **Relapse Free Survival** | | 62 (25) | | | |
| **GR** | Low | 39 (17) | 1 | | |
| | High | 23 (15) | 0.7726 | 0.3443-1.734 | 0.5458 |
| **Overall Survival** | | 62 (25) | | | |
| **GR** | Low | 39 (17) | 1 | | |
| | High | 23 (15) | 0.7301 | 0.3271-1.630 | 0.4610 |

**B**

| TMA #4 Anthracycline | | N (n) | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| **Relapse Free Survival** | | 41 (13) | | | |
| **GR** | Low | 21 (5) | 1 | | |
| | High | 20 (8) | 0.5175 | 0.1736-1.542 | 0.2390 |
| **Overall Survival** | | 41 (13) | | | |
| **GR** | Low | 21 (5) | 1 | | |
| | High | 20 (8) | 0.4929 | 0.1649-1.473 | 0.2038 |